Abstract:ABSTRACT The increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) has sparked global concern due to the dwindling availability of effective antibiotics. To increase our treatment options, researchers have investigated naturally occurring antimicrobial compounds and have identified MC21-A (C58), which has potent antimicrobial activity against MRSA. Recently, we have devised total synthesis schemes for C58 and its chloro-analog, C59. Here, we report that both compounds eradicate 90% of the 39 MRSA isolates tested [MIC 90 and minimum bactericidal concentration (MBC 90 )] at lower or comparable concentrations compared to several standard-of-care (SoC) antimicrobials including daptomycin, vancomycin, and linezolid. Furthermore, a stable, water-soluble sodium salt of C59, C59Na, demonstrates antimicrobial activity comparable to C59. C59, unlike vancomycin, kills stationary-phase MRSA in a dose-dependent manner and completely eradicates MRSA biofilms. In contrast to vancomycin, exposing MRSA to sub-MIC concentrations of C59 does not result in the emergence of spontaneous resistance. Similarly, in a multi-step study, C59 demonstrates a low propensity of resistance acquisition when compared to SoC antimicrobials, such as linezolid and clindamycin. Our findings suggest C58, C59, and C59Na are non-toxic to mammalian cells at concentrations that exert antimicrobial activity; the lethal dose at median cell viability (LD 50 ) is at least fivefold higher than the MBC 90 in the two mammalian cell lines tested. A morphological examination of the effects of C59 on a MRSA isolate suggests the inhibition of the cell division process as a mechanism of action. Our results demonstrate the potential of this naturally occurring compound and its analogs as non-toxic next-generation antimicrobials to combat MRSA infections IMPORTANCE The rapid emergence of methicillin-resistant Staphylococcus aureus (MRSA) isolates has precipitated a critical need for novel antibiotics. We have developed a one-pot synthesis method for naturally occurring compounds such as MC21-A (C58) and its chloro-analog, C59. Our findings demonstrate that these compounds kill MRSA isolates at lower or comparable concentrations to standard-of-care (SoC) antimicrobials. C59 eradicates MRSA cells in biofilms, which are notoriously difficult to treat with SoC antibiotics. Additionally, the lack of resistance development observed with C59 treatment is a significant advantage when compared to currently available antibiotics. Furthermore, these compounds are non-toxic to mammalian cell lines at effective concentrations. Our findings indicate the potential of these compounds to treat MRSA infections and underscore the importance of exploring natural products for novel antibiotics. Further investigation will be essential to fully realize the therapeutic potential of these next-generation antimicrobials to address the critical issue of antimicrobial resistance.

Natural Flavones from Morus Alba Against Methicillin-Resistant Staphylococcus Aureus Via Targeting the Proton Motive Force and Membrane Permeability

A Dual Mechanism with H2S Inhibition and Membrane Damage of Morusin from Morus Alba Linn. Against MDR-MRSA

Synergism of prenylflavonoids from Morus alba root bark against clinical MRSA isolates

Bioguided isolation, identification and bioactivity evaluation of anti-MRSA constituents from Morus alba Linn.

Flavonoids from Sophora Moorcroftiana and Their Synergistic Antibacterial Effects on Mrsa

Synergistic Antibacterial and Antibiofilm Effects of Ultrasound and MEL-A Against Methicillin-Resistant Staphylococcus Aureus

Novel Antibacterial Modalities Against Methicillin Resistant Staphylococcus Aureus Derived from Plants

Prenylated phenolics from Morus alba against MRSA infections as a strategy for wound healing

Natural Prenylflavonoids from Sophora flavescens Root Bark against Multidrug-Resistant Methicillin-Sensitive Staphylococcus aureus Targeting the Membrane Permeability

Plant Natural Flavonoids Against Multidrug Resistant Pathogens

Structure optimizing of flavonoids against both MRSA and VRE

Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential Against Methicillin-Resistant Staphylococcus Aureus (MRSA).

Molecular docking and proteomics reveals the synergistic antibacterial mechanism of theaflavin with β-lactam antibiotics against MRSA

Novel Tricyclic Flavonoids as Promising Anti-MRSA Agents

Phytochemical and anti-MRSA constituents of Zanthoxylum nitidum

Antimicrobial activity of a natural compound and analogs against multi-drug-resistant Gram-positive pathogens

Natural Antibacterial and Antivirulence Alkaloids From Macleaya cordata Against Methicillin-Resistant Staphylococcus aureus

Quinoline-based Anti-Mrsa Agents: Current Development, Structure-Activity Relationships, and Mechanisms

[Advances in the Study of Anti-Mrsa Natural Products].

A novel α-mangostin derivative synergistic to antibiotics against MRSA with unique mechanisms

Antimicrobial Effects and Resistant Regulation of Magnolol and Honokiol on Methicillin-Resistant Staphylococcus aureus